Split History
ETFs Holding CATB »    CATB Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Co.'s primary product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells in development for the treatment of Duchenne muscular dystrophy. Co. has also developed CAT-5571 as a treatment for cystic fibrosis. CAT-5571 is a conjugate that contains cysteamine, a naturally occurring molecule that is a degradation product of the amino acid cysteine, and docosahexaenoic acid, based on Co.'s proprietary Safely Metabolized And Rationally Targeted linker drug discovery platform. According to our CATB split history records, Catabasis Pharmaceuticals has had 2 splits.
CATB split history picture
Catabasis Pharmaceuticals (CATB) has 2 splits in our CATB split history database. The first split for CATB took place on December 28, 2018. CATB's second split took place on December 31, 2018. This was a 1 for 10 reverse split, meaning for each 10 shares of CATB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as Catabasis Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CATB split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Catabasis Pharmaceuticals shares, starting with a $10,000 purchase of CATB, presented on a split-history-adjusted basis factoring in the complete CATB split history. CATB split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 06/25/2015
End date: 12/13/2019
Start price/share: $130.00
End price/share: $5.53
Dividends collected/share: $0.00
Total return: -95.75%
Average Annual Total Return: -50.65%
Starting investment: $10,000.00
Ending investment: $425.22
Years: 4.47
Date Ratio
12/28/20181 for 1
12/31/20181 for 10
CATB is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CBIO Split History
CBLI Split History
CBM Split History
CBMX Split History
CBRX Split History
CCM Split History
CDXC Split History
CELG Split History
CERE Split History
CERU Split History

Also explore: CATB shares outstanding history

Protalix BioTherapeutics, Inc. (PLX)
Euroseas Ltd. (ESEA)
QuickLogic Corporation (QUIK)
iMedia Brands, Inc. (IMBI)
Akers Biosciences, Inc. (AKER)
NeuroMetrix, Inc. (NURO)
TRACON Pharmaceuticals (TCON)
SELLAS Life Sciences Group, Inc. (SLS)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Camber Energy, Inc. (CEI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CATB Insider Buying

CATB Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.